Idiosyncratic toxicity: a convergence of risk factors.

The therapeutic margin for any drug is based on both toxicity and efficacy. Generally, toxicity is dose-dependent and is driven either by the therapeutic target or by an untoward target. However, idiosyncratic toxicities are usually not observed until a drug has been on the market and has gained broad exposure. Except in the case of pharmacokinetic interactions, these toxicities are not driven solely by drug exposure but rather depend on several drug- and patient-related risk factors. Drug-related risk factors include metabolism, bioactivation and covalent binding, and the inhibition of key cell functions. Patient-related risk factors include underlying disease, age, gender, comedications, nutritional status, activation of the innate immune system, physical activity, and genetic predispositions. Idiosyncratic toxicity can occur when a convergence of risk factors, including drug exposure, tips the risk-benefit balance away from benefit and toward risk.

[1]  I. Leclercq,et al.  NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. , 2005, Gastroenterology.

[2]  J. Luyendyk,et al.  Ranitidine Treatment during a Modest Inflammatory Response Precipitates Idiosyncrasy-Like Liver Injury in Rats , 2003, Journal of Pharmacology and Experimental Therapeutics.

[3]  D. Pessayre,et al.  Hepatotoxicity due to mitochondrial dysfunction , 2004, Cell Biology and Toxicology.

[4]  P. Waller,et al.  Is Aspirin a Cause of Reye’s Syndrome? , 2004, Drug Safety.

[5]  K. Criswell,et al.  Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[6]  Zachary Simmons,et al.  Genetic risk factors associated with lipid‐lowering drug‐induced myopathies , 2006, Muscle & nerve.

[7]  R. Reye,et al.  ENCEPHALOPATHY AND FATTY DEGENERATION OF THE VISCERA. A DISEASE ENTITY IN CHILDHOOD. , 1963, Lancet.

[8]  Tieli Wang,et al.  The role of NF-κB in the regulation of cell stress responses , 2002 .

[9]  J. Waring,et al.  Preclinical Profiling and Safety Studies of ABT‐769: A Compound with Potential for Broad‐spectrum Antiepileptic Activity , 2005, Epilepsia.

[10]  B. K. Park,et al.  Role of bioactivation in drug-induced hypersensitivity reactions , 2006, The AAPS Journal.

[11]  D. Pessayre,et al.  Inhibition by salicylic acid of the activation and thus oxidation of long chain fatty acids. Possible role in the development of Reye's syndrome. , 1991, The Journal of pharmacology and experimental therapeutics.

[12]  D. Unnikrishnan,et al.  Exertion-induced rhabdomyolysis in a patient on statin therapy. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  J. Hanlon,et al.  Adverse drug reaction risk factors in older outpatients. , 2003, The American journal of geriatric pharmacotherapy.

[14]  M. Huang,et al.  Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs , 2005, Clinical pharmacokinetics.

[15]  Claude Lenfant,et al.  ACC/AHA/NHLBI clinical advisory on the use and safety of statins. , 2002, Journal of the American College of Cardiology.

[16]  Michel Eichelbaum,et al.  Pharmacogenomics and individualized drug therapy. , 2006, Annual review of medicine.

[17]  M. Pirmohamed,et al.  Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. , 2002, Molecular pharmacology.

[18]  D. Pessayre,et al.  Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. , 2006, Mitochondrion.

[19]  Sigal Kaplan,et al.  Reported adverse drug events in infants and children under 2 years of age. , 2002, Pediatrics.

[20]  P. Njølstad,et al.  Medium chain acyl-CoA dehydrogenase deficiency and fatal valproate toxicity. , 1997, Pediatric neurology.

[21]  S. Spielberg,et al.  Peroxidase-dependent oxidation of sulfonamides by monocytes and neutrophils from humans and dogs. , 1990, Molecular pharmacology.

[22]  K. Otani,et al.  Associations Between Risk Factors for Valproate Hepatotoxicity and Altered Valproate Metabolism , 1992, Epilepsia.

[23]  J. Waring,et al.  Microarray Analysis of Lipopolysaccharide Potentiation of Trovafloxacin-Induced Liver Injury in Rats Suggests a Role for Proinflammatory Chemokines and Neutrophils , 2006, Journal of Pharmacology and Experimental Therapeutics.

[24]  Marina Núñez,et al.  Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. , 2006, Journal of hepatology.

[25]  M. Braun,et al.  Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[26]  L. Romics,et al.  Diverse regulation of NF‐κB and peroxisome proliferator‐activated receptors in murine nonalcoholic fatty liver , 2004, Hepatology.

[27]  D. Amacher.  Drug-associated mitochondrial toxicity and its detection. , 2005, Current medicinal chemistry.

[28]  H. Colak,et al.  A case of rhabdomyolysis induced acute renal failure secondary to statin-fibrate-derivative combination and occult hypothyroidism. , 2005, Clinical nephrology.

[29]  K. Gempel,et al.  Acute Valproate Poisoning: Pharmacokinetics, Alteration in Fatty Acid Metabolism, and Changes During Therapy , 2005, Journal of clinical psychopharmacology.

[30]  William M. Lee.  Acetaminophen and the U.S. acute liver failure study group: Lowering the risks of hepatic failure , 2004, Hepatology.

[31]  John D Lambris,et al.  A high‐fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF‐κB inhibitor, IκBα , 2005 .

[32]  G. Granneman,et al.  The Hepatotoxicity of Valproic Acid and Its Metabolites in Rats. II. Intermediary and Valproic Acid Metabolism , 1984, Hepatology.

[33]  S. Dudoit,et al.  Exploration of global gene expression in human liver steatosis by high-density oligonucleotide microarray , 2006, Laboratory Investigation.

[34]  G. Farrell,et al.  Nonalcoholic fatty liver disease: From steatosis to cirrhosis , 2006, Hepatology.

[35]  Dominic P. Williams,et al.  Idiosyncratic toxicity: the role of toxicophores and bioactivation. , 2003, Drug discovery today.

[36]  M. Drici,et al.  Is Gender a Risk Factor for Adverse Drug Reactions? , 2001, Drug safety.

[37]  L. Laine,et al.  A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience , 2006, Pharmacoepidemiology and drug safety.

[38]  E. Roberts,et al.  Pemoline hepatotoxicity in children. , 1998, The Journal of pediatrics.

[39]  S. Nelson,et al.  Structure toxicity relationships--how useful are they in predicting toxicities of new drugs? , 2001, Advances in experimental medicine and biology.

[40]  F. Moreno,et al.  Carnitine levels in valproic acid-treated psychiatric patients: a cross-sectional study. , 2005, The Journal of clinical psychiatry.

[41]  P. Ventura,et al.  Selective depletion of mitochondrial glutathione content by pivalic acid and valproic acid in rat liver: possibility of a common mechanism. , 1996, Advances in experimental medicine and biology.

[42]  M. Murray.  Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis. , 2006, Current drug metabolism.

[43]  N. Fischel‐Ghodsian.  Genetic Factors in Aminoglycoside Toxicity , 1999, Pharmacogenomics.

[44]  Jill P. Smith,et al.  Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis c: a case series , 1998, American Journal of Gastroenterology.

[45]  J. Waring,et al.  Microvesicular Steatosis Induced by a Short Chain Fatty Acid: Effects on Mitochondrial Function and Correlation with Gene Expression , 2004, Toxicologic pathology.

[46]  Ò. Miró,et al.  Mitochondrial Studies in Haart-Related Lipodystrophy: From Experimental Hypothesis to Clinical Findings , 2005, Antiviral therapy.

[47]  Masao Honda,et al.  cDNA microarray analysis of autoimmune hepatitis, primary biliary cirrhosis and consecutive disease manifestation. , 2005, Journal of autoimmunity.

[48]  E. Kilbourne,et al.  Tryptophan produced by Showa Denko and epidemic eosinophilia-myalgia syndrome. , 1996, The Journal of rheumatology. Supplement.

[49]  M. Pirmohamed,et al.  Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. , 1992, British journal of clinical pharmacology.

[50]  J. Lindon,et al.  Pharmaco-metabonomic phenotyping and personalized drug treatment , 2006, Nature.

[51]  H. Sherratt.  Hypoglycin, the famous toxin of the unripe Jamaican ackee fruit , 1986 .

[52]  H. Cortez‐Pinto,et al.  Hepatocyte Apoptosis, Expression of Death Receptors, and Activation of NF-κB in the Liver of Nonalcoholic and Alcoholic Steatohepatitis Patients , 2004, The American Journal of Gastroenterology.

[53]  E. Björnsson,et al.  Suspected drug-induced liver fatalities reported to the WHO database. , 2006, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[54]  Adriane Fugh-Berman,et al.  Herb-drug interactions , 2000, The Lancet.

[55]  M. Salvi,et al.  Oxidative Stress Is Responsible for Mitochondrial Permeability Transition Induction by Salicylate in Liver Mitochondria* , 2005, Journal of Biological Chemistry.

[56]  Nelson.  Behavioral ecology of young-of-the-year kelp rockfish, Sebastes atrovirens Jordan and Gilbert (Pisces: Scorpaenidae). , 2001, Journal of experimental marine biology and ecology.

[57]  C. Pedone,et al.  Socio-demographic factors related to the prevalence of adverse drug reaction at hospital admission in an elderly population. , 2005, Archives of gerontology and geriatrics.

[58]  L. Stephen.  Drug Treatment of Epilepsy in Elderly People , 2003, Drugs & aging.

[59]  S. McClave,et al.  Nutritional supplements and alternative medicine , 2004, Current opinion in gastroenterology.

[60]  A. Diehl,et al.  Fatty liver vulnerability to endotoxin-induced damage despite NF-kappaB induction and inhibited caspase 3 activation. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[61]  V. Pichette,et al.  Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[62]  A. Diehl,et al.  Cytokines and the pathogenesis of non-alcoholic steatohepatitis , 2005, Gut.

[63]  J. Frank.  Diagnosis and management of G6PD deficiency. , 2005, American family physician.

[64]  N. Kaplowitz,et al.  Usnic acid-induced necrosis of cultured mouse hepatocytes: inhibition of mitochondrial function and oxidative stress. , 2004, Biochemical pharmacology.

[65]  G. Mahady.  Global harmonization of herbal health claims. , 2001, The Journal of nutrition.

[66]  B. Rumack.  Acetaminophen overdose in young children. Treatment and effects of alcohol and other additional ingestants in 417 cases. , 1984, American journal of diseases of children.

[67]  R. Sterling,et al.  Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection. , 2004, Seminars in liver disease.

[68]  G. Kemp,et al.  Aerobic exercise and muscle metabolism in patients with mitochondrial myopathy , 2006, Muscle & nerve.

[69]  Sonu Sundd Singh,et al.  Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. , 2006, Current drug metabolism.

[70]  U. Boelsterli,et al.  Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. , 2003, Toxicology and applied pharmacology.

[71]  T. Riley,et al.  Risk Factors and Ultrasound Can Predict Chronic Hepatitis Caused by Nonalcoholic Fatty Liver Disease , 2006, Digestive Diseases and Sciences.

[72]  P. Thompson,et al.  Lovastatin increases exercise-induced skeletal muscle injury. , 1997, Metabolism: clinical and experimental.

[73]  W. Marcason.  What is the bottom line for dietary guidelines when taking monoamine oxidase inhibitors? , 2005, Journal of the American Dietetic Association.

[74]  Ò. Miró,et al.  Mitochondrial toxicity associated with linezolid. , 2005, The New England journal of medicine.

[75]  P. Woster,et al.  A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. , 2000, The Journal of investigative dermatology.

[76]  G. Eisenbrand.  Toxicological evaluation of red mould rice. , 2006, Molecular nutrition & food research.

[77]  Edmund Jon Deoon Lee,et al.  Herbal bioactivation: The good, the bad and the ugly , 2003, Life Sciences.

[78]  T. Salazar-Mather,et al.  Cytokine and chemokine networks: pathways to antiviral defense. , 2006, Current topics in microbiology and immunology.

[79]  T. Davern,et al.  Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group. , 2000, Digestive diseases and sciences.

[80]  M. Wanscher,et al.  [Acute valproate poisoning]. , 1987, Ugeskrift for laeger.

[81]  K. Reddy,et al.  Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. , 2004, Journal of hepatology.

[82]  A. Mitra,et al.  MDR- and CYP3A4-mediated drug-herbal interactions. , 2006, Life sciences.

[83]  K. Olive,et al.  Chinese Red Rice-induced Myopathy , 2003, Southern medical journal.

[84]  W. Hwu,et al.  Metabolic disorders mimicking Reye's syndrome. , 2000, Journal of the Formosan Medical Association = Taiwan yi zhi.

[85]  Neil Kaplowitz,et al.  Liver biology and pathobiology , 2006, Hepatology.

[86]  R. Holman,et al.  Reye's syndrome in the United States from 1981 through 1997. , 1999, The New England journal of medicine.

[87]  H. Scholte,et al.  Mitochondrial Injury , 1997, Drug safety.

[88]  A. Gasbarrini,et al.  Fatty liver and drugs. , 2005, European review for medical and pharmacological sciences.

[89]  D. Elliott,et al.  Grapefruit juice and potential drug interactions. , 2003, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[90]  N. P. Lee,et al.  Fulminant Liver Failure Due to Usnic Acid for Weight Loss , 2004, American Journal of Gastroenterology.

[91]  R. Ulrich,et al.  Metabolic, idiosyncratic toxicity of drugs: overview of the hepatic toxicity induced by the anxiolytic, panadiplon. , 2001, Chemico-biological interactions.

[92]  T. Baillie,et al.  Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. , 2004, Chemical research in toxicology.

[93]  Bridget Wilcken,et al.  Strategies for the diagnosis of mitochondrial fatty acid β-oxidation disorders , 2002 .

[94]  M. Lapeyre-Mestre,et al.  Gender differences in adverse drug reactions: analysis of spontaneous reports to a Regional Pharmacovigilance Centre in France , 2002, Fundamental & clinical pharmacology.

[95]  R. Anderson,et al.  Dinitrophenol in weight loss: the poison center and public health safety. , 1986, Veterinary and human toxicology.

[96]  J. Luyendyk,et al.  Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. , 2004, Chemico-biological interactions.

[97]  L. Bowman,et al.  Adverse drug reaction (ADR) occurrence and evaluation in elderly inpatients , 1996, Pharmacoepidemiology and drug safety.

[98]  J. Staffa,et al.  Rhabdomyolysis with HMG‐CoA reductase inhibitors and gemfibrozil combination therapy , 2004, Pharmacoepidemiology and drug safety.